首页> 美国卫生研究院文献>BMC Biotechnology >Critical assessment of influenza VLP production in Sf9 and HEK293 expression systems
【2h】

Critical assessment of influenza VLP production in Sf9 and HEK293 expression systems

机译:对Sf9和HEK293表达系统中流感VLP产生的关键评估

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundEach year, influenza is responsible for hundreds of thousand cases of illness and deaths worldwide. Due to the virus’ fast mutation rate, the World Health Organization (WHO) is constantly on alert to rapidly respond to emerging pandemic strains. Although anti-viral therapies exist, the most proficient way to stop the spread of disease is through vaccination. The majority of influenza vaccines on the market are produced in embryonic hen’s eggs and are composed of purified viral antigens from inactivated whole virus. This manufacturing system, however, is limited in its production capacity. Cell culture produced vaccines have been proposed for their potential to overcome the problems associated with egg-based production. Virus-like particles (VLPs) of influenza virus are promising candidate vaccines under consideration by both academic and industry researchers.
机译:背景每年,流感是导致全球数十万例疾病和死亡的原因。由于该病毒的快速突变率,世界卫生组织(WHO)时刻保持警惕,以迅速应对新出现的大流行毒株。尽管存在抗病毒疗法,但阻止疾病传播的最有效方法是接种疫苗。市场上的大多数流感疫苗都是用母鸡的卵生产的,并由灭活的全病毒纯化的病毒抗原组成。但是,该制造系统的生产能力受到限制。已经提出了细胞培养生产的疫苗的潜力,以克服与蛋基生产相关的问题。流行性感冒病毒的病毒样颗粒(VLP)是有前途的候选疫苗,学术界和行业研究人员均在考虑之中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号